[Acellular pertussis vaccine]

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• The development of effective and safe pertussis vaccines is crucial for public health.
• Traditional whole-cell pertussis vaccines have been associated with adverse effects, leading to the development of acellular pertussis vaccines (aPV).

Purpose of the Study:

• To evaluate the protective, immunogenic, toxic, and sensitizing properties of a domestically developed acellular pertussis vaccine (aPV).
• To compare the efficacy and safety profile of aPV with a standard pertussis bacteria suspension (PS).

Main Methods:

• Animal models (mice, guinea pigs, rabbits) were used to assess vaccine efficacy and safety.
• Immunogenicity was evaluated by measuring antibody levels (IgG to pertussis toxin).
• Toxicity was assessed through tests for pyrogenicity, anaphylaxis, and histamine sensitization.

Main Results:

• The aPV exhibited marked protective activity lasting over 2 years.
• Immune sera from aPV-immunized mice showed higher protective properties and neutralizing activity against pertussis toxin (PT) compared to sera from PS-immunized mice.
• The aPV demonstrated significantly lower toxicity, with 40 times less histamine-sensitizing ability and 1,000 times lower pyrogenicity than PS.

Conclusions:

• The domestic acellular pertussis vaccine (aPV) possesses high protective and immunogenic properties.
• aPV exhibits significantly reduced toxicity and sensitizing characteristics compared to pertussis bacteria suspension (PS).
• These findings support the use of this aPV as a safe and effective pertussis vaccine.